Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastroenteropancreatic Neuroendocrine Tumor: full-pipeline trial registry
4 of 8 indexed Gastroenteropancreatic Neuroendocrine Tumor trials are currently recruiting.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 4 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Gastroenteropancreatic Neuroendocrine Tumor: 8 US clinical trials tracked, 4 recruiting.
Gastroenteropancreatic Neuroendocrine Tumor is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Advanced Accelerator Applications, running 1 of these trials.
Enrollment posture brief
Registry condition gastroenteropancreatic-neuroendocrine-tumor
OPEN 4 | RECR 50% | LATE 3 | EARLY 3 | RANK #2176 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Gastroenteropancreatic Neuroendocrine Tumor lists 4 open slots (50% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastroenteropancreatic Neuroendocrine Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastroenteropancreatic Neuroendocrine Tumor is recruiting above its size-band peers.
4 of 8 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Gastroenteropancreatic Neuroendocrine Tumor trials is spread across many organizations.
Advanced Accelerator Applications accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Gastroenteropancreatic Neuroendocrine Tumor enrolment sits around 260 participants.
Median target enrolment is 260 among the 8 trials that report a genuine target (sentinel values excluded). 3 of those (37.5%) plan for fewer than 100 participants.
-
Gastroenteropancreatic Neuroendocrine Tumor research is mostly interventional.
6 interventional and 2 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RayzeBio
NCT05477576
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
Perspective Therapeutics
NCT05636618
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
Methodist Health System
NCT04090034
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
Stanford University
NCT04609592
Neuroendocrine Tumors - Patient Reported Outcomes
University of Iowa
NCT05064150
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
Camurus AB
NCT05050942
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Advanced Accelerator Applications
NCT03972488
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Amr Mohamed MD
NCT05262556
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastroenteropancreatic Neuroendocrine Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastroenteropancreatic Neuroendocrine Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastroenteropancreatic Neuroendocrine Tumor page
8 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Gastroenteropancreatic Neuroendocrine Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Accelerator Applications sponsors the most Gastroenteropancreatic Neuroendocrine Tumor trials on record, review their full trial history before evaluating a specific study. See Advanced Accelerator Applications's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastroenteropancreatic Neuroendocrine Tumor condition card totals 8 registered trials; most-linked intervention Lutathera; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.